About the Serum Urate as a Clinically Valid Surrogate in Gout Working Group

Gout is caused by an increase in blood uric acid levels that leads to deposition of uric acid crystals in the joints. These crystals can cause gout flares which manifest as severely painful swollen joints. There are two general treatment strategies, firstly to treat gout flares and secondly to lower the blood uric acid levels in order to prevent the flares from occurring in the first place. It is recommended that a certain level of uric acid in the blood is reached (<0.36mmol/l; 6mg/dl) and that if this is sustained over time the gout flares will reduce and eventually stop. The strength of this relationship between lowering blood uric acid levels and reducing gout flares is the main focus of this working group

Robin Christensen

Robin Christensen

Co-Chair

Jasvinder-A-Singh-Final

Jasvinder A. Singh

Co-Chair

lisa stamp

Lisa Stamp

Co-Chair

Melanie Morillon

Melanie Morillon

Fellow

Metter Birthe Pedersen

Patient Research Partner

OMERACT 2020 Virtual Serum Urate Special Interest Group Session

Working Group Publications

Working Group Members:

Lisa Stamp
Jas Singh
Robin Christensen
Metter Birthe Pedersen
Martin Kennedy
Melanie Morillon
Lee Simon

Jayne, David
Kermani, Tanaz
Langford, Carol
Lanier, Georgia
Mackie, Sarah
Mahr, Alfred
Meara, Alexa
Milman, Nataliya
Ozguler, Yesim

Pagnoux, Christian
Robson, Joanna
Shea, Beverly
Tómasson, Gunnar
Merkel, Peter
Milman, Nataliya
Monti, Sara
Quinn, Kaitlin
Tugwell, Peter

Scroll to Top